2020-07-25| StartupsTechnology

Spotlight on Startups! LuminX – Nano-diamond for Cell Labeling and Tracking

by GeneOnline
Share To

LuminX is a startup company established in 2020. It provides preclinical one-stop solutions for therapeutic cells. While tracking cells in vivo through traditional methods such as PCR or imaging only provide very limited information. Those products lack accurate and rapid pre-clinical cell pharmacokinetic verification. Therefore, when cells are used as drugs in organisms, how to monitor cell positioning, quantification effectively, and validation analysis are significant challenges. The CEO of LuminX, Dr. Harry Su, applied the Nano-diamond technology developed from Academia Sinica and National Taiwan University into a one-stop cell pharmacokinetic testing platform, providing cell GPS positioning in vivo after cells are injected into the organism. It has six significant advantages:

1. Can be used in large animal models (pigs)
2. PK/PD of transplanted-cells
3. Background-free imaging
4. Single-cell detection sensitivity
5. High throughput quantification
6. No interference with cell potency

Currently, they have cooperated with many hospitals, including Kaohsiung Medical University, National Taiwan University Hospital, National Taiwan University, Taipei Medical University, and have contracts with several clinical trial service CRO companies.

Since its establishment, LuminX has won several awards for innovative projects, including being selected for the 2020 Digital Health International Accelerator Team, DCB International Innovation Accelerator, and more. This year’s BIO ASIA-TAIWAN LuminX is also selected as the Innovation team by the Ministry of Science and Technology.

To learn more about LuminX’s technology, please visit them during BIO Asia-Taiwan this week or join virtually in the company presentation.

© All rights reserved. Collaborate with us: [email protected]
Related Post
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
Scroll to Top